沉浸式VR技术分散注意力对缓解儿童PICC置管疼痛的效果:一项随机对照研究

注册号:

Registration number:

ChiCTR2600124868 

最近更新日期:

Date of Last Refreshed on:

2026-05-18 17:38:55 

注册时间:

Date of Registration:

2026-05-18 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

沉浸式VR技术分散注意力对缓解儿童PICC置管疼痛的效果:一项随机对照研究

Public title:

The effect of immersive VR technology on relieving pain during PICC placement in children: a randomized controlled study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

沉浸式VR技术分散注意力对缓解儿童PICC置管疼痛的效果:一项随机对照研究

Scientific title:

The effect of immersive VR technology on relieving pain during PICC placement in children: a randomized controlled study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王冲 

研究负责人:

王冲 

Applicant:

Wang Chong 

Study leader:

Wang Chong 

申请注册联系人电话:

Applicant telephone:

+86 138 1106 6280

研究负责人电话:

Study leader's
telephone:

+86 138 1106 6280

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wangchong2026@126.com

研究负责人电子邮件:

Study leader's E-mail:

wangchong2026@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国北京市海淀区羊坊店铁医路10号

研究负责人通讯地址:

中国北京市海淀区羊坊店铁医路10号

Applicant address:

10 Tieyi Road, Yangfangdian, Haidian District, Beijing, China

Study leader's address:

10 Tieyi Road, Yangfangdian, Haidian District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京世纪坛医院

Applicant's institution:

Beijing Shijitan Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学附属北京世纪坛医院

Affiliation of the Leader:

Beijing Shijitan Hospital, Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

ky-2026-0029-002

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学附属北京世纪坛医院伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Beijing Shijitan Hospital, Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2026-05-11 00:00:00

伦理委员会联系人:

李继红

Contact Name of the ethic committee:

Li Jihong

伦理委员会联系地址:

中国北京市海淀区羊坊店铁医路10号

Contact Address of the ethic committee:

10 Tieyi Road, Yangfangdian, Haidian District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 6392 6342

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学附属北京世纪坛医院

Primary sponsor:

Beijing Shijitan Hospital, Capital Medical University

研究实施负责(组长)单位地址:

中国北京市海淀区羊坊店铁医路10号

Primary sponsor's address:

10 Tieyi Road, Yangfangdian, Haidian District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京世纪坛医院

具体地址:

中国北京市海淀区羊坊店铁医路10号

Institution
hospital:

Beijing Shijitan Hospital, Capital Medical University

Address:

10 Tieyi Road, Yangfangdian, Haidian District, Beijing, China

经费或物资来源:

自筹

Source(s) of funding:

Self-funded

研究疾病:

接受PICC置管的儿童  

Target disease:

Children requiring a PICC

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究评估沉浸式VR技术对缓解儿童PICC置管疼痛与焦虑的有效性,旨在为儿科疼痛管理提供临床医学证据。其科学价值在于验证“注意分散理论”在非药物疼痛干预中的应用,推动非药物镇痛方法在儿童疼痛中的管理,显著减轻患儿在留置PICC过程中的身心创伤,体现医学治疗中的人文关怀。同时,方案预期能提升护士操作效率与成功率,节约医疗资源,并以其简便、安全的特性,具备在各类儿科有创操作场景中推广的潜力。  

Objectives of Study:

This study evaluates the effectiveness of immersive VR technology in alleviating pain and anxiety in children undergoing PICC insertion, aiming to provide clinical evidence for pediatric pain management. Its scientific value lies in validating the application of the distraction theory in non‑pharmacological pain interventions, advancing the management of non‑pharmacological analgesic methods for pediatric pain, significantly reducing the physical and psychological trauma of children during PICC placement, and reflecting the humanistic care inherent in medical treatment. Furthermore, this intervention is expected to improve nursing efficiency and success rates, conserve medical resources, and, owing to its simplicity and safety, holds potential for generalization across various pediatric invasive procedures.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 各种原因导致置管未完成者; 2. 家属及患儿任何原因要求退出研究。

Exclusion criteria:

1. Those who fail to complete the catheter insertion due to any reason; 2. Those whose families or the child request withdrawal from the study for any reason.

研究实施时间:

Study execute time:

From 2026-05-25 00:00:00 To 2028-03-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-05-25 00:00:00 To 2028-03-31 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

44

Group:

Control group

Sample size:

干预措施:

常规PICC护理

干预措施代码:

Intervention:

Routine PICC care

Intervention code:

组别:

试验组

样本量:

44

Group:

Trial group

Sample size:

干预措施:

虚拟现实(VR眼镜)干预

干预措施代码:

Intervention:

Receive virtual reality (VR glasses) intervention in addition to routine PICC care

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京世纪坛医院 

单位级别:

三甲 

Institution
hospital:

Beijing Shijitan Hospital, Capital Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

面部表情疼痛量表

指标类型:

主要指标

Outcome:

Wong-Baker FACES Pain Rating Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

状态焦虑量表

指标类型:

次要指标

Outcome:

State Anxiety Inventory

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心智游移单因素自我报告量表

指标类型:

次要指标

Outcome:

Mind Wandering Questionnaire

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良反应记录表

指标类型:

副作用指标

Outcome:

Adverse Event Record Form

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 6 years
最大 Max age 12 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

利用SPSS 22.0生成随机数88个,将试验组和对照组按1:1的比例,试验组44例、对照组44例

Randomization Procedure (please state who generates the random number sequence and by what method):

Using SPSS 22.0, 88 random numbers were generated, and participants were allocated to the experimental group and the control group at a 1:1 ratio, with 44 cases in the experimental group and 44 cases in the control group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

本研究采用单盲(结局评估者盲)设计。受试者与干预实施者:由于VR干预需患儿主动佩戴眼镜,且护士可观察到操作过程,因此无法对受试者及PICC置管护士实施盲法。结局评估者:所有疼痛及焦虑相关结局(如面部表情疼痛量表评分、焦虑评分等)均由一名独立研究助理完成,该助理不参与随机分组、不进入置管室,且对患儿分组情况不知情。评估前,助理会再次确认患儿及家属未透露干预方式。数据分析师:统计分析阶段,数据将被编码并隐藏分组信息,直至主要分析完成,以确保结果的客观性。

Blinding:

This study employed a single‑blind (outcome assessor‑blinded) design. Participants and intervention providers: Because the VR intervention required children to actively wear the glasses and the nurses could observe the procedure, blinding of the participants and the nurses performing PICC insertion was not feasible. Outcome assessor: All pain‑ and anxiety‑related outcomes (e.g., Faces Pain Scale – Revised score, anxiety score) were assessed by an independent research assistant who was not involved in randomization, did not enter the PICC room, and was unaware of the children’s group allocation. Prior to each assessment, the assistant verified that the child and family had not disclosed the intervention received. Data analyst: During the statistical analysis phase, the data were coded and group allocation was concealed until the primary analysis was completed to ensure the objectivity of the results.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结束后半年;国家生物信息中心(https://www.cncb.ac.cn/)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Six months after the completion of the research; China National Center for Bioinformation (https://www.cncb.ac.cn/)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

研究采用纸质病例记录表(CRF)采集原始数据,CRF基于研究方案设计,涵盖人口学信息、纳入/排除标准、结局指标(FPS‑R、焦虑评分等)、操作记录及不良反应等模块。CRF由研究者根据病历和观察结果在操作后24小时内填写完毕,并遵循CRF填写指南。使用ResMan临床试验公共管理平台(www.medresman.org.cn)作为电子数据采集系统(EDC),采用双人双次录入并核对,系统自动比对不一致处,由数据管理员进行逻辑一致性及缺失值核查。纸质CRF按编号归档并加锁保存>=5年,电子数据双备份。所有参与数据工作的人员均经统一培训,数据录入人员不参与干预实施,数据管理员定期监查并生成核查报告,最终数据库锁定前由主要研究者审核。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The study uses paper Case Record Forms (CRFs) to collect raw data. The CRFs are designed based on the study protocol and cover modules including demographic information, inclusion/exclusion criteria, outcome measures (FPS‑R score, anxiety score, etc.), procedure records, and adverse reactions. The CRFs are completed by the investigators within 24 hours after the procedure based on medical records and observations, following a CRF completion guide. The ResMan Clinical Trial Public Management Platform (www.medresman.org.cn) is used as the Electronic Data Capture (EDC) system. Double data entry and verification (two independent entries) are performed, and the system automatically compares discrepancies. The data administrator performs logical consistency and missing value checks. The paper CRFs are archived by patient number and stored in a locked cabinet for >=5 years. Electronic data are double‑backed up. All personnel involved in data handling receive standardized training. Data entry staff do not participate in intervention implementation. The data administrator regularly monitors the data and generates audit reports. The final database lock is reviewed and approved by the principal investigator.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-05-18 17:38:49